Florida-based Breckenridge Pharmaceutical has announced the launch of its azelastine HCl nasal spray, a generic version of Meda’s Astelin, after receiving final FDA approval of its ANDA. The product is approved for the treatment of seasonal allergic rhinitis in patients aged 5 years and older for the treatment of vasomotor rhinitis in patients 12 years and older.
Read the Breckenridge press release.
